Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Joseph P. Balthasar"'
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 649-664 (2021)
Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor
Externí odkaz:
https://doaj.org/article/2129f05e18514c9faccbb101a265fdbb
Publikováno v:
Cancers, Vol 15, Iss 3, p 713 (2023)
Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of potent cytotoxic agents t
Externí odkaz:
https://doaj.org/article/8940595a7572497d9d1c8348c9aed238
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 1, p 475 (2022)
Small therapeutic proteins are receiving increased interest as therapeutic drugs; however, their clinical success has been limited due to their rapid elimination. Here, we report a half-life extension strategy via strategy via red blood cell red bloo
Externí odkaz:
https://doaj.org/article/19f2fea4a573472090640d6b81da03cd
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Our group has developed and experimentally validated a strategy to increase antibody penetration in solid tumors through transient inhibition of antibody-antigen binding. In prior work, we demonstrated that 1HE, an anti-trastuzumab single domain anti
Externí odkaz:
https://doaj.org/article/cc63e946d6224bcfbf2533c43a6dc300
Autor:
Brandon M. Bordeau, Joseph Ryan Polli, Ferdinand Schweser, Hans Peter Grimm, Wolfgang F. Richter, Joseph P. Balthasar
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 2, p 679 (2022)
The prediction of monoclonal antibody (mAb) disposition within solid tumors for individual patients is difficult due to inter-patient variability in tumor physiology. Improved a priori prediction of mAb pharmacokinetics in tumors may facilitate the d
Externí odkaz:
https://doaj.org/article/bb9ee826976d45c298ea729290726f22
Publikováno v:
Cancer Biology & Medicine, Vol 11, Iss 1, Pp 20-33 (2014)
Since the approval of rituximab in 1997, monoclonal antibodies (mAbs) have become an increasingly important component of therapeutic regimens in oncology. The success of mAbs as a therapeutic class is a result of great strides that have been made in
Externí odkaz:
https://doaj.org/article/0ae2976e2f0e47e9b89952ceb2052405
Autor:
Tommy Li, Joseph P. Balthasar
Publikováno v:
Biomolecules, Vol 8, Iss 4, p 115 (2018)
Quantitative real-time PCR and Western blot methods were developed to assess neonatal Fc-receptor (FcRn) mRNA and protein expression in human FcRn transgenic mice, Swiss Webster mice, and in select human tissues. Additionally, FcRn turnover was evalu
Externí odkaz:
https://doaj.org/article/22011c8ba0a04f98a2a08e43f61eaf7d
Autor:
Shun Xin Wang-Lin, Joseph P. Balthasar
Publikováno v:
Antibodies, Vol 7, Iss 1, p 5 (2018)
Antibiotic-resistant bacterial pathogens are increasingly implicated in hospital- and community-acquired infections. Recent advances in monoclonal antibody (mAb) production and engineering have led to renewed interest in the development of antibody-b
Externí odkaz:
https://doaj.org/article/f817213ea44c472d9cbdd995c0e53e32
Publikováno v:
Molecular Cancer Therapeutics. 22:459-470
Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for four FDA-approved antibody–drug conjugates (ADC). Deconjugated MMAE readily diffuses into untargeted cells, resulting in off-target toxicity. Here, we repo
Publikováno v:
Mol Cancer Ther
We have recently shown that coadministration of mAbs with anti-idiotypic distribution enhancers (AIDE) that inhibit mAb binding to tumor antigens enabled increased intratumoral mAb distribution and increased efficacy of an antibody–drug conjugate (